Identifying diagnostic biomarkers and therapeutic strategies
The VirPath team, at the International Center for Infectiology Research in Lyon, has been working since early 2020 on Covid-19. Its aim is to better understand the biology of the virus to allow the prognosis and/or diagnosis of the related pathology, and to provide appropriate therapeutic strategies. The VirPath team has developed an infection model for SARS-CoV-2 in a reconstituted human respiratory epithelium model in order to conduct its research as closely as possible to real conditions.
|Project initiator: International Center for Infectiology Research (CIRI), Virology and human Pathology laboratory - VirPath, Claude Bernard Lyon University||Years of support: 2020|
Location: Lyon, France
|Amount provided: EUR 50,000|
Characterization of the biology of SARS-CoV-2
The aim of Dr. Terrier and the VirPath team at the International Center for Infectiology Research (CIRI) is to generate new data on the biology of SARS-CoV-21 to identify the biomarkers for prognosis and/or diagnosis and future anti-viral strategies.
In order to characterize the biology of SARS-CoV-2 and its related pathology, Dr. Terrier and the CIRI team are studying the following:
- on the one hand, the infection’s impact on the physiology of the reconstituted human respiratory epithelium
- on the other hand, the cellular responses to the infection on the molecular genetic scale
1. Severe Acute Respiratory Syndrome coronavirus 2
An experimental pre-clinical model
To allows this work to take place, Olivier Terrier and his colleagues have developed an infection model for SARS-CoV-2 in a reconstituted human respiratory epithelium model. This experimental pre-clinical model enables the assessment of treatments in conditions closest to the physiology of the respiratory tract. The respiratory epithelium’s functions include pulmonary ventilation, defense and conditioning of inhaled air; it plays a central role in the early stages of the infection.
The team at CIRI has been working since mid-January 2020. It has managed to isolate several strains of SARS-CoV-2 using samples from the first cases in France, hospitalized at Bichat hospital in Paris. The team started a program to identify medications that are already authorized on the market and that could be used for their anti-viral properties. The team has been involved in the pre-clinical evaluation of several candidate medications that are now in the clinical trial phase.
©International Center for Infectiology Research in Lyon / SARS-CoV-2 coronavirus attached to the cilia of human respiratory epithelial cells. This is one of the very first images of the SARS-CoV-2 virus isolated from patients.
How the Air Liquide Foundation is participating
The Air Liquide Foundation is assisting with the acquisition of a fluorescent microscope, reagents and consumables.
Discover other projects we support
Study of biomarkers of Covid-19 aggravation
Clinicians are observing a delayed worsening after 7 days in certain patients suffering from Covid-19.
Improving bedside ventilation monitoring
A portable ultrasound scanner to monitor the condition of patients in intensive care and make work easier for caregivers
Respiratory Complications in Patients with Severe Cases of COVID-19
Conducting a two-year study of respiratory function in COVID-19 patients at Cochin Hospital in Paris
Human and animal exposure to the SARS-Cov-2 virus via inhaled air
Quantitative evaluation of human and animal exposure via inhaled air within the context of the COVID-19 pandemic and evaluation of risk reduction measures